Article Text

Download PDFPDF
Efficacy of rituximab in Felty’s syndrome
  1. V Lekharaju,
  2. C Chattopadhyay
  1. Department of Rheumatology, Wrightington Hospital, Wrightington, UK
  1. Dr V Lekharaju, Staff Grade in Rheumatology, Department of Rheumatology, Wrightington Hospital, Hall Lane, Appley Bridge, Wrightington WN6 9EP, UK; lekharajupawan{at}

Statistics from

Felty’s syndrome (FS) is associated with rheumatoid arthritis (RA) in conjunction with neutropenia and splenomegaly. The mechanisms underlying neutropenia of FS may involve both cellular and humoral immunity, with a possible role of granulocyte-colony stimulation factor (G-CSF) antibodies.1 Various disease-modifying antirheumatic drugs have been used to treat FS with varying success.2 G-CSF raises neutrophil count and reduces infection in some cases of FS.3 Rituximab, a monoclonal antibody specific for human CD20, which targets B lymphocytes, has been tried in the treatment of FS in the past with mixed results.4 We describe a patient with FS who was treated …

View Full Text


  • Competing interests: None.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.